New Recruiting Trial: Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma
WHY IT MATTERS
This trial is now recruiting patients with clear cell renal cell carcinoma at a major Chinese hospital — if you have this kidney cancer diagnosis, you may be eligible to access experimental combination treatment before standard treatment options.
Researchers are testing a new treatment approach for clear cell renal cell carcinoma, a type of kidney cancer. The study combines two types of drugs: immunotherapy (which helps your immune system fight cancer) and a targeted therapy drug (TKI) that blocks specific cancer growth signals. This trial is now accepting patients and will test whether giving these drugs before and after surgery helps patients live longer.
NCT ID: NCT07571551 Title: Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma Status: RECRUITING Phase: PHASE2 Sponsor: Jinling Hospital, China Start date: 2026-05-06 URL: https://clinicaltrials.gov/study/NCT07571551 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If you have been diagnosed with clear cell renal cell carcinoma, contact Jinling Hospital or check clinicaltrials.gov (NCT07571551) immediately to learn about eligibility requirements and enrollment.